ICAP’s Jessica Justman, MD, senior technical director, was featured in a Nov. 24 article by Time Magazine, which discussed AztraZeneca’s COVID-19 vaccine and why its efficacy varies so much. The data, part of a scheduled efficacy review, is based on 131 cases of COVID-19 among both the vaccinated and placebo groups. But because the full set of data has not been published, vaccine experts—including regulators—are still trying to figure out why the different regimens led to different results. Justman says:

“The different levels of efficacy with two different dosing regimens is scientifically intriguing.”

Read the full article in Time Magazine 

Read the latest ICAP updates on COVID-19 here

A major global health organization that has been improving public health in countries around the world for over 15 years, ICAP works to transform the health of populations through innovation, science, and global collaboration. Based at Columbia University in New York City, where it is part of the Mailman School of Public Health, ICAP has projects in more than 30 countries, working side-by-side with ministries of health and local partners to confront some of the world’s toughest health challenges. Through meaningful research, tailored technical assistance, effective training and education programs, and rigorous surveillance to measure and evaluate the impact of public health interventions, ICAP aims to realize a global vision of healthy people, empowered communities, and thriving societies. Online at icap.columbia.edu

Related Items